Cost of Care for Juvenile Idiopathic Arthritis

NeuroTherapia, Inc.

Status: Completed

Conditions: Juvenile Idiopathic Arthritis

Study type: Observational

Funder types: Other

Identifiers

NCT01469897

CCF 11-291

Details and patient eligibility

About

This project seeks to collect data on healthcare utilization and expenditure rates in Juvenile Idiopathic Arthritis (JIA) patients from across the US, correlate these costs with disease activity and outcome measures and determine methods by which to reduce the economic impact while improving outcomes.

Full description

SPECIFIC AIMS AND OBJECTIVES

The specific aims of this registry protocol are:

• To create and maintain a secure online database of patients with JIA
• To collect data elements related to cost of care in patients with JIA
• Compare standard outcome and disease activity measures to health care expenditures in JIA
• To determine methods by which to reduce costs while improving outcomes and quality of care

The study plans to enroll 300 or more subjects from 3 medical centers in the US over a 24 month period. Subjects in the study are patients with Juvenile Idiopathic Arthritis.

Enrollment into the protocol will include key demographic and clinical data including, medication exposures, disease severity, and function including disease-specific data elements; and estimates of health care service utilization and health care expenditures. Data will be collected once per subject within the context of a standard of care visit.

Enrollment: 165 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject has been diagnosed with JIA by a pediatric rheumatologist according to published criteria.
• Person providing consent must be able to read English.
• Subject (and/or parent/legal guardian) is able to provide informed consent and willing to comply with study procedures.

Exclusion criteria

• Subject/ legal guardian is unwilling to provide consent, cannot read English, or does not meet published criteria for JIA.
• Coexisting rheumatologic disorder
• Diagnosis of fibromyalgia
• Participation in a drug trial in the past 6 months.